ChartRow logo
Data provided bySource: Twelve Data
SMMT
$10.67-9.73%
as of close, Nov 17, 2026
☾ AH $10.67 -9.73%
PeersBBIOBNTXASNDARGXGHPRAX
Share this page

SMMT financial statements

The full income statement, balance sheet, and cash-flow statement for Summit Therapeutics Inc. Common Stock (SMMT), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Financial overview#

Revenue

5Y n/m5Y n/mYoY n/m
— FY25— Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Gross profit

— FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Operating income

5Y n/m5Y n/mYoY n/m
— FY25— Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25
Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m10Y n/mYoY n/m
−$832.7M TTM−$208.4M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m5Y n/mYoY n/m
−$1.07 TTM−$0.26 Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating cash flow

5Y n/m10Y n/mYoY n/m
−$525.2M TTM−$159.8M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Capital expenditure

5Y CAGR +9.3%10Y CAGR +20.7%YoY +457.7%
$1.7M TTM$396K Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m10Y n/mYoY n/m
−$526.9M TTM−$160.2M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Shares (diluted)

5Y +975.5%5Y +975.5%YoY +7.4%
779.6M TTM798.2M Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Every SMMT chart on Trends →

Shares outstanding (point-in-time)

2024-09 737.4M2024-12 737.7M2025-03 742.7M2025-06 742.8M2025-09 744.4M2025-12 775.4M2026-03 776.2M2026-06 797.7M2026-09 799.8M+8.5% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

PeriodRangeOrderChangeFiguresAs-reported fiscal years.
Line itemTrendFY2025FY2024FY2023FY2022FY2021
Income Statementas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Revenue—0.000.00-100.0%705K-61.0%1.81M+110.3%
1.09B+384.3%226M-62.9%610M+599.1%87.2M-20.0%109M+48.5%
Research & development538M+256.6%151M+153.5%59.5M+14.4%52.0M-39.1%85.4M+60.2%
Selling, general & administrative557M+824.6%60.2M+105.8%29.3M+9.4%26.7M+13.3%23.6M+22.8%
General & administrative557M+824.6%60.2M+105.8%29.3M+9.4%26.7M+13.3%23.6M+22.8%
Amortization of intangibles—0.000.00-100.0%914K-10.1%1.02M-18.6%
Operating income—-226M+62.9%-610M-745.7%-72.1M+16.4%-86.2M-62.0%
Interest expense0.00-100.0%8.69M-47.2%16.5M+274.0%4.40M+1718.6%242K-5.1%
Interest & investment income———1.51M0.00-100.0%
Other non-operating income-53.0K0.00+100.0%-252K-182.9%304K+112.6%-2.42M-953.7%
Pre-tax income-1.08B-387.8%-221M+64.0%-615M-680.5%-78.8M+11.1%-88.6M-67.5%
Income tax0.000.000.00—0.00+100.0%
-1.08B-387.8%-221M+64.0%-615M-680.5%-78.8M+11.1%-88.6M-68.1%
Net income to common-1.08B-387.8%-221M+64.0%-615M-680.5%-78.8M+11.1%-88.6M-68.1%
-$1.44-364.5%-$0.31+68.7%-$0.99-141.5%-$0.41+38.8%-$0.67+11.8%
EPS (basic)-$1.44-364.5%-$0.31+68.7%-$0.99-141.5%-$0.41+38.8%-$0.67+11.8%
Weighted-avg shares (basic)748M+4.1%719M+16.0%620M+220.5%193M+46.8%132M+89.5%
Weighted-avg shares (diluted)748M+4.1%719M+16.0%620M+220.5%193M+46.8%132M+89.5%
Balance Sheetas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
720M+70.0%424M+123.4%190M-71.1%657M+574.9%97.3M+11.0%
Cash & equivalents225M+114.8%105M+46.8%71.4M-79.5%349M+385.6%71.8M+8.1%
Short-term investments488M+58.8%307M+167.8%115M0.00—
Cash & short-term investments
——186M——
Accounts receivable——0.00-100.0%349K-76.2%1.46M+342.3%
Prepaid expenses6.54M-41.0%11.1M+322.4%2.62M+74.3%1.50M-79.0%7.16M-25.0%
Other current assets——181K-62.8%486K-59.5%1.20M-21.1%
751M+72.5%436M+114.6%203M-69.4%664M+485.8%113M+10.6%
Property, plant & equipment1.06M+316.9%254K+24.5%204K-77.5%906K+30.5%694K-4.3%
Operating lease right-of-use20.6M+188.6%7.14M+21.9%5.86M+40.3%4.17M+49.6%2.79M+403.6%
Goodwill2.00M+7.3%1.86M-1.5%1.89M+5.3%1.80M-10.5%2.01M-1.0%
Intangible assets—0.000.000.00-100.0%10.4M-9.7%
Other non-current assets7.21M+182.8%2.55M-41.0%4.32M+649.0%577K+239.4%170K
73.0M+74.9%41.7M+104.5%20.4M-47.4%38.8M+51.4%25.6M+28.8%
Accounts payable20.3M+337.7%4.64M+73.8%2.67M+651.3%355K-91.9%4.37M-28.8%
Accrued liabilities32.1M+64.2%19.6M+122.6%8.78M-17.6%10.7M+48.2%7.20M+119.6%
Deferred revenue———0.00-100.0%7.94M-5.1%
Short-term & current debt——0.00-100.0%19.8M—
Current lease liability3.39M-10.0%3.77M+34.0%2.81M+66.2%1.69M+54.9%1.09M+179.7%
Other current liabilities2.28M+27.0%1.80M+150.6%717K+8.3%662K-26.2%897K+23.0%
92.3M+97.2%46.8M-62.6%125M-76.7%538M+1686.4%30.1M+30.6%
Long-term debt—0.00-100.0%100M-79.8%495M—
Deferred revenue (non-current)———0.000.00-100.0%
Non-current lease liability17.5M+406.9%3.45M+5.0%3.29M+19.1%2.76M+63.4%1.69M+2154.7%
Operating lease liability (total)20.9M+189.4%7.22M+18.3%6.10M+37.0%4.45M+60.1%2.78M+498.3%
Other non-current liabilities1.83M+12.4%1.63M+4.4%1.56M+9.3%1.43M-48.5%2.78M+10.6%
659M+69.5%389M+400.4%77.7M-38.7%127M+52.1%83.3M+4.8%
Preferred stock0.000.000.000.000.00
Common stock7.75M+5.1%7.38M+5.1%7.02M+232.6%2.11M+115.3%980K+18.6%
Additional paid-in capital2.95B+84.4%1.60B+49.9%1.07B+111.3%505M+31.4%384M+30.9%
Retained earnings-2.29B-88.9%-1.21B-22.3%-993M-162.5%-378M-26.3%-300M-42.0%
Accumulated other comprehensive income-2.54M-11.2%-2.29M+6.7%-2.45M-29.3%-1.89M+13.8%-2.20M+42.1%
Total equity incl. non-controlling659M+69.5%389M+400.4%77.7M-38.7%127M+52.1%83.3M+4.8%
Total liabilities & equity751M+72.5%436M+114.6%203M-69.4%664M+485.8%113M+10.6%
Common shares issued775M+5.1%738M+5.1%702M+232.4%211M+115.3%98.0M+18.7%
Common shares outstanding775M+5.1%738M+5.1%702M+232.4%211M+115.3%98.0M+18.7%
Shares outstanding (cover)775M+5.1%738M+5.1%702M+0.6%698M+611.0%98.1M+18.3%
Cash Flowas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
-323M-127.2%-142M-85.1%-76.8M-84.6%-41.6M+42.7%-72.6M-50.9%
Depreciation & amortization146K+64.0%89.0K-55.1%198K-84.3%1.26M-6.2%1.35M-13.2%
Intangible amortization—0.000.00-100.0%914K-10.1%1.02M-18.6%
Share-based compensation732M+1336.7%51.0M+261.4%14.1M+18.1%11.9M-6.7%12.8M+625.0%
Deferred income taxes
————0.00
Change in receivables—0.00+100.0%-359K+63.2%-975K-185.7%1.14M+636.8%
Change in payables15.3M+659.5%2.02M-11.0%2.26M+154.8%-4.13M-141.5%-1.71M-204.2%
-174M+15.1%-205M+65.1%-588M-94094.6%-624K-103.9%-306K+27.3%
Capital expenditure657K+372.7%139K+8.6%128K-79.5%624K+103.9%306K-27.3%
Free cash flow-324M-127.5%-142M-85.0%-76.9M-82.2%-42.2M+42.1%-72.9M-50.2%
Acquisitions0.000.000.000.000.00
Proceeds from sale of PP&E0.000.00-100.0%226K0.00—
618M+62.0%381M+340.7%86.5M-86.1%620M+696.0%77.9M+54.1%
Long-term debt issued0.000.000.000.000.00
Long-term debt repaid0.000.000.000.000.00
Common stock issued—0.00-100.0%105M+4.7%100M+33.3%75.0M+50.0%
Common stock repurchased0.000.000.000.000.00
Dividends paid0.000.000.000.000.00
FX effect on cash
————351K-36.9%
Net change in cash120M+256.6%33.8M+105.8%-577M-200.1%577M+10633.5%5.37M+108.7%
Interest paid0.00-100.0%8.81M-17.3%10.7M+2353.9%434K+410.6%85.0K
Income taxes paid0.000.00-100.0%52.0K0.00-100.0%7.00K+110.0%
Valuation Ratiosas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Market cap13.6B+3.0%13.2B+619.6%1.83B+113.8%856M+224.2%264M-32.3%
P/S———895.0×+513.4%145.9×-67.8%
P/B20.6×-39.2%33.9×+84.0%18.4×+186.6%6.4×+102.6%3.2×-35.4%
Source filing10-K10-K10-K10-K10-K/A
Fiscal yearCEOTotal, as reportedActually paidOther executives, average$100 in the stock$100 in peers
FY2025Mahkam Zanganeh $246M / $233.1MRobert W. Duggan $172.4K / $172.4K$246.2M$233.3M$249.1M$372.13$119.92
FY2024Mahkam Zanganeh $1.2M / $228.3MRobert W. Duggan $158.6K / $158.6K$1.3M$228.5M$2.5M$379.57$113.68
FY2023Mahkam Zanganeh$20.6M$30.1M$12M$55.53$115.84
FY2022Mahkam Zanganeh$1.2M$3.8M$1.4M$90.43$111.67
FY2021Mahkam Zanganeh$9.6M$5.1M$1.3M$57.23$126.42

From the pay-versus-performance table of each proxy statement (DEF 14A), the newest that states the year. “Actually paid” values stock awards at the year’s closing price, so it falls when the stock does. A year two chief executives shared lists each one’s pay, as reported / actually paid, and the totals are both. $100 in the stock and in the peer group the proxy names are the newest proxy’s, from the start of its first year.

About this data

Source: SMMT’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all SMMT filings on SEC EDGAR → Not investment advice.